Rocket Pharmaceuticals, Inc.
RCKT
NASDAQ·Healthcare·Biotechnology·Mkt cap $421.5M
$3.86
▲ +1.85%
P/E
-24.13
Mkt Cap
$421.5M
52-Wk Range
$2.53–$5.45
52-Week Range
$2.53 - $5.45
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 18.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary multi-platform gene therapy technology (ex vivo lentiviral and in vivo AAV)
- Strategic partnerships with world-leading research institutions and biotech companies
- Focus on rare genetic diseases with high unmet medical needs and limited competition
- Clinical-stage programs with potential first-in-class or best-in-class positioning
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Advancement of four clinical-stage gene therapy programs toward regulatory milestones
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+43.0% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying RCKT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 10, 2026
Reported EPS of $1.08 vs $0.86 consensus (+25.6% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+25.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Chardan Capital · May 11, 2026
vs Industry
How RCKT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related